REVIEW

Anti-tumour necrosis factor therapy in rheumatoid arthritis: an update on safety

K L Hyrich, A J Silman, K D Watson, D P M Symmons

ARC Epidemiology Unit, University of Manchester, UK

Correspondence to:
Professor A J Silman
ARC Epidemiology Unit, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK; alan.Silman{at}man.ac.uk

Anti-TNF therapy may have associated risks of serious infection, congestive heart failure, malignancy, and multiple sclerosis. The magnitude of these risks is difficult to assess. This article reviews publications on the current knowledge about the safety of these agents.

Abbreviations: ANA, antinuclear antibody; CHF, congestive heart failure; DMARD, disease modifying antirheumatic drug; dsDNA, double stranded DNA; FDA, Federal Drug Administration; MS, multiple sclerosis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TB, tuberculosis; TNF, tumour necrosis factor

Keywords: anti-tumour necrosis factor ; rheumatoid arthritis; safety

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Somers, E. C., Thomas, S. L., Smeeth, L., Hall, A. J. (2009). Are Individuals With an Autoimmune Disease at Higher Risk of a Second Autoimmune Disorder?. Am J Epidemiol 169: 749-755 [Abstract] [Full Text]  
• Furst, D E, Keystone, E C, Kirkham, B, Fleischmann, R, Mease, P, Breedveld, F C, Smolen, J S, Kalden, J R, Burmester, G R, Braun, J, Emery, P, Winthrop, K, Bresnihan, B, De Benedetti, F, Dorner, T, Gibofsky, A, Schiff, M H, Sieper, J, Singer, N, Van Riel, P L C M, Weinblatt, M E, Weisman, M H (2008). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 67: iii2-iii25 [Full Text]  
• Voulgari, P V, Markatseli, T E, Exarchou, S A, Zioga, A, Drosos, A A (2008). Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis 67: 567-570 [Abstract] [Full Text]  
• Dinser, R., Fousse, M., Sester, U., Albrecht, K., Singh, M., Kohler, H., Muller-Ladner, U., Sester, M. (2008). Evaluation of latent tuberculosis infection in patients with inflammatory arthropathies before treatment with TNF-{alpha} blocking drugs using a novel flow-cytometric interferon-{gamma} release assay. Rheumatology (Oxford) 47: 212-218 [Abstract] [Full Text]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Sieper, J, Emery, P, Keystone, E C, Schiff, M H, Mease, P, van Riel, P L C M, Fleischmann, R, Weisman, M H, Weinblatt, M E (2007). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 66: iii2-iii22 [Full Text]  
• Sheppard, J., Raza, K., Buckley, C. D. (2007). Skin cancer in psoriatic arthritis treated with anti-TNF therapy. Rheumatology (Oxford) 46: 1622-1623 [Full Text]  
• Kuek, A., Hazleman, B. L, Ostor, A. J K (2007). Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad. Med. J. 83: 251-260 [Abstract] [Full Text]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Emery, P, Keystone, E C, Schiff, M H, van Riel, P L C M, Weinblatt, M E, Weisman, M H (2006). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis 65: iii2-iii15 [Full Text]  
• Douglas, K M J, Ladoyanni, E, Treharne, G J, Hale, E D, Erb, N, Kitas, G D (2006). Cutaneous abnormalities in rheumatoid arthritis compared with non-inflammatory rheumatic conditions. Ann Rheum Dis 65: 1341-1345 [Abstract] [Full Text]  
• Friese, M. A., Montalban, X., Willcox, N., Bell, J. I., Martin, R., Fugger, L. (2006). The value of animal models for drug development in multiple sclerosis. Brain 129: 1940-1952 [Abstract] [Full Text]  
• Zhang, H.-G., Liu, C., Su, K., Yu, S., Zhang, L., Zhang, S., Wang, J., Cao, X., Grizzle, W., Kimberly, R. P. (2006). A Membrane Form of TNF-{alpha} Presented by Exosomes Delays T Cell Activation-Induced Cell Death.. J. Immunol. 176: 7385-7393 [Abstract] [Full Text]  
• Massara, A., Cavazzini, P. L., Trotta, F. (2006). In SAPHO syndrome anti-TNF-{alpha} therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology (Oxford) 45: 730-733 [Abstract] [Full Text]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Bijlsma, J W J, Dougados, M, Emery, P, Keystone, E C, Klareskog, L, Mease, P J (2005). Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 64: iv2-iv14 [Full Text]  
• Frostegard, J. (2005). Atherosclerosis in Patients With Autoimmune Disorders. Arterioscler. Thromb. Vasc. Bio. 25: 1776-1785 [Abstract] [Full Text]  
• Chevillotte-Maillard, H., Ornetti, P., Mistrih, R., Sidot, C., Dupuis, J., Dellas, J.-A., Tavernier, C., Maillefert, J. F. (2005). Survival and safety of treatment with infliximab in the elderly population. Rheumatology (Oxford) 44: 695-696 [Full Text]  
• Rott, S., Mrowietz, U. (2005). Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies. BMJ 330: 716-720 [Full Text]